First-line maintenance treatment with olaparib provides long-term progression-free survival (PFS) benefit in BRCA-mutated advanced ovarian cancer at five-year follow-up of SOLO-1 phase III trial

In patients who had previously demonstrated a complete or partial response following platinum-based chemotherapy, olaparib improved PFS to a median of 56.0 months vs. 13.8 months with placebo; and reduced risk of disease progression or death by 67%.

Source:

PharmaTimes